

## Technology Appraisal Committee Meeting (Committee C)

**Minutes:** **Confirmed**

**Date and Time:** **Wednesday 11 May, 10:00 to14:30**

**Venue:** National Institute for Health and Care Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BT

<b>Present:</b>	1. Chair Professor Andrew Stevens 2. Professor Kathryn Abel 3. Dr Ian Bernstein 4. David Chandler 5. Professor Rachel Elliott 6. Dr Nigel Langford 7. Professor Andrea Manca 8. Dr Iain Miller 9. Dr Paul Miller 10. Professor Stephen O'Brien 11. Dr Anna O'Neill 12. Professor Andrew Renehan 13. Dr Peter Selby 14. Prof Matt Stevenson 15. Dr Paul Tappenden 16. Dr Judith Wardle	Present for all notes Present for all notes
-----------------	--	--

### **In attendance:**

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Stephanie Yates	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Joanne Ekeledo	Administrator, National Institute for Health and Care Excellence	Present for all notes

Henry Edwards	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 04 to 08
Joanne Holden	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 04 to 08
Stuart Wood	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 09 to 12
Nicola Hay	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 09 to 12

**Non-public observers:**

Ewen Cummins	ERG representative	Present for notes 04 to 07
Neil Scott	ERG representative	Present for notes 04 to 07
Noemi Lois	ERG representative	Present for notes 04 to 07
Ruben Mujica-Mota	ERG representative	Present for notes 04 to 07
Irina Tikhonova	ERG representative	Present for notes 04 to 07
Dr Ian Pearce	Clinical Expert	Present for notes 04 to 07
Dr Winfred Amoaku	Clinical Expert	Present for notes 04 to 07
Professor Subbiyan Rajendran	Patient Expert	Present for notes 04 to 07
Mrs Melba Ryde	Patient Expert	Present for notes 04 to 08
Gabriel Rogers	NICE Observer	Present for notes 04 to 08
Gemma Smith	NICE Observer	Present for all notes
Kate Moring	NICE Observer	Present for all notes
Sam Parker	NICE Observer	Present for notes 04 to 08
Stephanie Birtles	NICE Observer	Present for all notes

**Notes**

**Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of afibercept for treating visual impairment caused by macular oedema in branch retinal vein occlusion and azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
2. Apologies were received from Professor Eugene Milne, Gail Coster and Dr Robert Walton

## **Any other Business**

3. None

### **Appraisal of afibercept for treating visual impairment caused by macular oedema in branch retinal vein occlusion**

#### **Part 1 – Open session**

4. The Chair welcomed the invited experts: Dr Ian Pearce, Dr Winfred Amoaku, Professor Subbiyan Rajendran and Mrs Melba Ryde to the meeting and they introduced themselves to the Committee.
5. The Chair welcomed company representatives from Bayer to the meeting.
6. The Chair asked all Committee members to declare any relevant interests
  - 6.1. Professor Kathryn Abel, Dr Ian Bernstein, David Chandler Professor Rachel Elliott, Dr Nigel Langford, Professor Andrea Manca Dr Iain Miller, Dr Paul Miller, Professor Stephen O'Brien, Dr Anna O'Neill Professor Andrew Renahan, Dr Peter Selby, Prof Matt Stevenson Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of afibercept for treating visual impairment caused by macular oedema in branch retinal vein occlusion
7. The Chair asked all NICE Staff to declare any relevant interests.
  - 7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of afibercept for treating visual impairment caused by macular oedema in branch retinal vein occlusion
8. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
  - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific

family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of aflibercept for treating visual impairment caused by macular oedema in branch retinal vein occlusion .

8.2. Dr Ian Pearce declared a personal non-specific financial interest as he has received consultancy and lecture fees from Bayer and Allegan.

8.2.1. It was agreed that this declaration would not prevent Dr Ian Pearce from participating in this section of the meeting

8.3. Dr Winfred Amoaku declared a personal non-specific financial interest as he has received consultancy fees from Bayer, Allegan, Novartis and Pfizer.

8.3.1. It was agreed that this declaration would not prevent Dr Winfred Amoaku from participating in this section of the meeting

9. The Chair introduced the lead team, Dr Andrea Manca, Professor Kathryn Abel and David Chandler who gave presentations on the clinical effectiveness and cost effectiveness of aflibercept for treating visual impairment caused by macular oedema in branch retinal vein occlusion

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

13. Discussion on confidential information continued. This information was supplied by the company.

14. The Committee continued to discuss the clinical and cost effectiveness of aflibercept for treating visual impairment caused by macular oedema in branch retinal vein occlusion .

15. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Appraisal of azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts**

## **Part 1 – Open session**

16. The Chair welcomed company representatives from Celgene to the meeting.

17. The Chair asked all Committee members to declare any relevant interests

17.1. Professor Kathryn Abel, Dr Ian Bernstein, David Chandler Professor Rachel Elliott, Dr Nigel Langford, Professor Andrea Manca Dr Iain Miller, Dr Paul Miller, Professor Stephen O'Brien, Dr Anna O'Neill Professor Andrew Renahan, Dr Peter Selby, Prof Matt Stevenson Dr Paul Tappenden and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts.

17.2. Professor Stephen O'Brien declared a non-personal specific non specific financial. He is a member of the NCRI Clinical Studies Group (CSG), which oversees a portfolio of leukaemia trials in the UK. I have no current involvement with CLL trials – my involvement is in CML. Non-reimbursed position.

9.2.1 It was agreed that this declaration would not prevent Professor Stephen O'Brien from participating in this section of the meeting.

18. The Chair asked all NICE Staff to declare any relevant interests.

18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts.

19. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts.

20. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

21. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

22. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

23. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

24. The Committee continued to discuss the clinical and cost effectiveness of azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
25. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Date, time and venue of the next meeting**

26. Wednesday 15 June 2016, 10:00 to 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT